Evidence map›Paper›PMID 25833838›Full record

ArticleMolecular cancer therapeutics2015

TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression.

Jin Zhu, Dong-Rong Yang, Yin Sun, Xiaofu Qiu, Hong-Chiang Chang, Gonghui Li, Yuxi Shan, Chawnshang Chang

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Dihydroartemisinin Prevents Distant Metastasis of Laryngeal Carcinoma by Inactivating STAT3 in Cancer Stem Cells.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Jin ZhuDepartment of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, China. George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
Dong-Rong YangDepartment of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, China. George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
Yin SunGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
Xiaofu QiuGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York. Department of Urology, Guangdong No. 2 Provincial People's Hospital, Guangzhou, China.
Hong-Chiang ChangGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York. Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
Gonghui LiGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
Yuxi ShanDepartment of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, China. George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York. chang@urmc.rochester.edu shanyx1002@aliyun.com.
Chawnshang ChangGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York. Sex Hormone Research Center, China Medical University/Hospital, Taichung, Taiwan. chang@urmc.rochester.edu shanyx1002@aliyun.com.
University of Rochester Medical Center · USChina Medical University · TW

Funding

Stromal AR Roles in Prostate Hyperplasia and CancerR01CA156700 · NCI · UNIVERSITY OF ROCHESTER · PI CHANG, CHAWNSHANG, YEH, SHUYUAN · 2011 to 2015
$1.6M
Loss of Androgen Receptor Promotes Metastatic Prostate CancerR01CA122840 · NCI · UNIVERSITY OF ROCHESTER · PI CHANG, CHAWNSHANG, YEH, SHUYUAN · 2007 to 2011
$1.5M
NCI NIH HHS CA122840NCI NIH HHS CA156700NCI NIH HHS R01 CA122840NCI NIH HHS R01 CA156700
6 · The paper itself

Abstract

The testicular nuclear receptor 4 (TR4) is a member of the nuclear receptor superfamily that mediates various biologic functions with key impacts on metabolic disorders and tumor progression. Here, we demonstrate that TR4 may play a positive role in prostate cancer CD133(+) stem/progenitor (S/P) cell invasion. Targeting TR4 with lentiviral silencing RNA significantly suppressed prostate cancer CD133(+) S/P cell invasion both in vitro and in vivo. Mechanism dissection found that TR4 transcriptionally regulates the oncogene EZH2 via binding to its 5' promoter region. The consequences of targeting TR4 to suppress EZH2 expression may then suppress the expression of its downstream key metastasis-related genes, including NOTCH1, TGFβ1, SLUG, and MMP9. Rescue approaches via adding the EZH2 reversed the TR4-mediated prostate cancer S/P cell invasion. Together, these results suggest that the TR4→EZH2 signaling may play a critical role in the prostate cancer S/P cell invasion and may allow us to develop a better therapy to battle the prostate cancer metastasis.

Indexed as

Gene Expression Regulation, NeoplasticAC133 AntigenAnimalsAntigens, CDBlotting, WesternCell Line, TumorCell MovementCells, CulturedEnhancer of Zeste Homolog 2 ProteinGlycoproteinsHumansMaleMice, NudeNeoplasm MetastasisNeoplastic Stem CellsPeptidesAC133 AntigenAntigens, CDEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanGlycoproteinsNR2C2 protein, humanPeptidesPolycomb Repressive Complex 2PROM1 protein, humanProm1 protein, mouseReceptor, Notch1Receptors, SteroidReceptors, Thyroid HormoneTransforming Growth Factor beta1

Identifiers

PMID25833838
PMCPMC4704461
OpenAlexW2145873105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.